Cargando…

Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation

BACKGROUND: Esophageal cancer (EC) is the sixth leading cause of cancer‐related death, despite many advances in treatment, the survival of patients still remains poor. In recent years, the N6‐methyladenosine (m6A) has been introduced as one of the most important modifications at the epitranscriptome...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramedani, Fahimeh, Jafari, Seyyed Mehdi, Saghaeian Jazi, Marie, Mohammadi, Zeinab, Asadi, Jahanbakhsh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026269/
https://www.ncbi.nlm.nih.gov/pubmed/36534072
http://dx.doi.org/10.1002/cnr2.1759
_version_ 1784909509325488128
author Ramedani, Fahimeh
Jafari, Seyyed Mehdi
Saghaeian Jazi, Marie
Mohammadi, Zeinab
Asadi, Jahanbakhsh
author_facet Ramedani, Fahimeh
Jafari, Seyyed Mehdi
Saghaeian Jazi, Marie
Mohammadi, Zeinab
Asadi, Jahanbakhsh
author_sort Ramedani, Fahimeh
collection PubMed
description BACKGROUND: Esophageal cancer (EC) is the sixth leading cause of cancer‐related death, despite many advances in treatment, the survival of patients still remains poor. In recent years, the N6‐methyladenosine (m6A) has been introduced as one of the most important modifications at the epitranscriptome level, with an important role in the mRNA regulation in various diseases, such as cancers. The m6A is regulated by different factors, including FTO as a demethylase. The m6A modification, especially through FTO overexpression has an oncogenic role in different cancer types such as EC. Recent studies showed that entacapone, a catechol‐o‐methyl transferase (COMT) inhibitor currently applied for Parkinson's disease, can inhibit FTO enzyme. AIMS: In this study, we aimed to investigate the effect of entacapone as an FTO inhibitor on the m6A level and also apoptosis and cell cycle response in KYSE‐30 and YM‐1 of esophageal squamous cancer cell (ESCC) lines. METHODS: Cell toxicity and IC50 of entacapone were evaluated using The MTT assay in YM‐1 and KYSE‐30 cells. Cells were treated into two groups: DMSO (control) and entacapone (mean IC(50)). Total RNA was extracted, and m6A levels were measured via the ELISA method. Subsequently, the apoptosis and cell cycle dys‐regulation were detected by annexin‐V‐FITC/PI staining and PI staining via flow cytometry. RESULTS: Entacapone has the cytotoxicity effect on both esophageal cancer cell lines compared to normal PBMC cells. As well, entacapone treatment (140 μM) can induce apoptosis (KYSE‐30: 50%. YM‐1:22.6%) and has a modulatory effect on cell cycle progression in both YM‐1 and KYSE‐30 cells (p‐value<.05). However, no significant difference in the m6A concentration was observed. CONCLUSION: Our findings suggested that entacapone has the inhibitory effect on ESCC cell lines through induction of the apoptosis and modulation of the cell cycle without toxicity on the normal PBMC.
format Online
Article
Text
id pubmed-10026269
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100262692023-03-21 Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation Ramedani, Fahimeh Jafari, Seyyed Mehdi Saghaeian Jazi, Marie Mohammadi, Zeinab Asadi, Jahanbakhsh Cancer Rep (Hoboken) Original Articles BACKGROUND: Esophageal cancer (EC) is the sixth leading cause of cancer‐related death, despite many advances in treatment, the survival of patients still remains poor. In recent years, the N6‐methyladenosine (m6A) has been introduced as one of the most important modifications at the epitranscriptome level, with an important role in the mRNA regulation in various diseases, such as cancers. The m6A is regulated by different factors, including FTO as a demethylase. The m6A modification, especially through FTO overexpression has an oncogenic role in different cancer types such as EC. Recent studies showed that entacapone, a catechol‐o‐methyl transferase (COMT) inhibitor currently applied for Parkinson's disease, can inhibit FTO enzyme. AIMS: In this study, we aimed to investigate the effect of entacapone as an FTO inhibitor on the m6A level and also apoptosis and cell cycle response in KYSE‐30 and YM‐1 of esophageal squamous cancer cell (ESCC) lines. METHODS: Cell toxicity and IC50 of entacapone were evaluated using The MTT assay in YM‐1 and KYSE‐30 cells. Cells were treated into two groups: DMSO (control) and entacapone (mean IC(50)). Total RNA was extracted, and m6A levels were measured via the ELISA method. Subsequently, the apoptosis and cell cycle dys‐regulation were detected by annexin‐V‐FITC/PI staining and PI staining via flow cytometry. RESULTS: Entacapone has the cytotoxicity effect on both esophageal cancer cell lines compared to normal PBMC cells. As well, entacapone treatment (140 μM) can induce apoptosis (KYSE‐30: 50%. YM‐1:22.6%) and has a modulatory effect on cell cycle progression in both YM‐1 and KYSE‐30 cells (p‐value<.05). However, no significant difference in the m6A concentration was observed. CONCLUSION: Our findings suggested that entacapone has the inhibitory effect on ESCC cell lines through induction of the apoptosis and modulation of the cell cycle without toxicity on the normal PBMC. John Wiley and Sons Inc. 2022-12-19 /pmc/articles/PMC10026269/ /pubmed/36534072 http://dx.doi.org/10.1002/cnr2.1759 Text en © 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Ramedani, Fahimeh
Jafari, Seyyed Mehdi
Saghaeian Jazi, Marie
Mohammadi, Zeinab
Asadi, Jahanbakhsh
Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation
title Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation
title_full Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation
title_fullStr Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation
title_full_unstemmed Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation
title_short Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation
title_sort anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026269/
https://www.ncbi.nlm.nih.gov/pubmed/36534072
http://dx.doi.org/10.1002/cnr2.1759
work_keys_str_mv AT ramedanifahimeh anticancereffectofentacaponeonesophagealcancercellsviaapoptosisinductionandcellcyclemodulation
AT jafariseyyedmehdi anticancereffectofentacaponeonesophagealcancercellsviaapoptosisinductionandcellcyclemodulation
AT saghaeianjazimarie anticancereffectofentacaponeonesophagealcancercellsviaapoptosisinductionandcellcyclemodulation
AT mohammadizeinab anticancereffectofentacaponeonesophagealcancercellsviaapoptosisinductionandcellcyclemodulation
AT asadijahanbakhsh anticancereffectofentacaponeonesophagealcancercellsviaapoptosisinductionandcellcyclemodulation